Bookmark and Share

Compound Summary for: CID 3000391

tetrachlorodecaoxide

Also known as: Oxilium; Tetrachlorodecaoxygen; TCDO; Ancloximex; Animexan; Oxocebron; Oxoferin; Oxomexan; Oxovasin
Molecular Formula: Cl4H2O11-4   Molecular Weight: 319.82128   InChIKey: VOWOEBADKMXUBU-UHFFFAOYSA-J
WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 2 sub-sections (Related Compounds, Related Substances)
Pharmacology
Biomedical Effects and Toxicity
Literature
Biomolecular Interactions and Pathways
Classification
Chemical and Physical Properties
_ _